pubmed.ncbi.nlm.nih.gov

Pregnancy Outcomes in HIV-Infected Women: Experience from a Tertiary Care Center in India - PubMed

Pregnancy Outcomes in HIV-Infected Women: Experience from a Tertiary Care Center in India

Vatsla Dadhwal et al. Int J MCH AIDS. 2017.

Abstract

Background and objectives: There is conflicting data on the effect of HIV infection as well as antiretroviral therapy (ART) on pregnancy outcome. The objectives of this study were to compare pregnancy outcomes in women with and without HIV infection, and to evaluate the effect of HAART on pregnancy in HIV-infected women.

Methods: This is a prospective case record analysis of 212 HIV-infected women delivering between 2002 and 2015, in a tertiary health care center in India. The pregnancy outcome in HIV-infected women was compared to 238 HIV-uninfected controls. Women received ART for prevention of mother to child transmission as per protocol which varied during the period of study. Effect of use of ART on preterm birth (PTB) and intrauterine growth restriction (IUGR) was analyzed.

Results: HIV-infected women were more likely to have PTB, IUGR, and anemia (9.4%, 9.9%, 5.2%) compared to uninfected women (7.6%, 5%, 3.8%), this did not reach statistical significance (P-value = >0.05). The incidence of PIH, diabetes mellitus and intrahepatic cholestasis of pregnancy was similar in both groups. Mean birth weight was significantly lower in neonates of HIV-infected women (2593.60±499g) than HIV-uninfected women (2919±459g) [P-value=0.001]. neonatal intensive care unit admissions were also significantly higher in infants born to HIV-infected women (P-value=0.002). HIV-infected women on ART had decreased incidence of PTB and IUGR.

Conclusion and global health implications: Good antenatal care and multidisciplinary team approach can optimize pregnancy outcomes in HIV-infected women.

Keywords: Antiretroviral Therapy; Human Immunodeficiency Virus; Intrauterine Growth Restriction; Preterm Birth.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflicts of interest.

Similar articles

Cited by

References

    1. World Health Organization (WHO) Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: Programmatic update. Geneva, Switzerland: WHO; 2012.
    1. Haeri S, Shauer M, Dale M, Leslie J, Baker AM, Saddlemire S, Boggess K. Obstetric and newborn infant outcomes in human immunodeficiency virus-infected women who receive highly active antiretroviral therapy. American Journal of Obstetrics and Gynecology. 2009;201:315, e1–5. - PubMed
    1. Ekouevi DK, Coffie PA, Becquet R, Tonwe Gold B, Horo A, Thiebaut R, Leroy V, Blanche S, Dabis F, Abrams EJ. Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d’Ivoire. AIDS. 2008;22(14):1815–20. - PubMed
    1. Baroncelli S, Tamburrini E, Ravizza M, et al. Antiretroviral treatment in pregnancy: A six-year perspective on recent trends in prescription patterns, viral load suppression, and pregnancy outcomes. AIDS Patient Care and STDS. 2009;23:513–520. - PubMed
    1. Darak S, Darak T, Kulkarni S, Kulkarni V, Parchure R, Hutter I, Janssen F. Effect of Highly Active Antiretroviral Treatment (HAART) During Pregnancy on Pregnancy Outcomes: Experiences from a PMTCT Program in Western India. AIDS Patient Care and STDs. 2013;27(3):163–170. - PubMed

LinkOut - more resources